{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:42:28Z","timestamp":1787020948405,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01AR064338-01A1"],"award-info":[{"award-number":["R01AR064338-01A1"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mick Hitchcock Scholarship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Skeletal Muscle"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Laminin-\u03b12-related congenital muscular dystrophy (LAMA2-CMD) is a devastating genetic disease caused by mutations in the LAMA2 gene. These mutations result in progressive muscle wasting and inflammation leading to delayed milestones, and reduced lifespan in affected patients. There is currently no cure or treatment for LAMA2-CMD. Preclinical studies have demonstrated that mouse laminin-111 can serve as an effective protein replacement therapy in a mouse model of LAMA2-CMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this study, we generated a novel immunocompromised dy\n                      <jats:sup>W<\/jats:sup>\n                      mouse model of LAMA2-CMD to study the role the immune system plays in muscle disease progression. We used this immune-deficient dy\n                      <jats:sup>W<\/jats:sup>\n                      mouse model to test the therapeutic benefits of recombinant human laminin-111 and laminin-211 protein therapy on laminin-\u03b12-deficient muscle disease progression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We show that immunodeficient laminin-\u03b12 null mice demonstrate subtle differences in muscle regeneration compared to immunocompetent animals during early disease stages but overall exhibit a comparable muscle disease progression. We found human laminin-111 and laminin-211 could serve as effective protein replacement strategies with mice showing improvements in muscle pathology and function. We observed that human laminin-111 and laminin-211 exhibit differences on satellite and myoblast cell populations and differentially affect muscle repair.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study describes the generation of a novel immunodeficient mouse model that allows investigation of the role the immune system plays in LAMA2-CMD. This model can be used to assess the therapeutic potential of heterologous therapies that would elicit an immune response. Using this model, we show that recombinant human laminin-111 can serve as effective protein replacement therapy for the treatment of LAMA2-CMD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13395-020-00235-4","type":"journal-article","created":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T01:02:29Z","timestamp":1591232549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Human laminin-111 and laminin-211 protein therapy prevents muscle disease progression in an immunodeficient mouse model of LAMA2-CMD"],"prefix":"10.1186","volume":"10","author":[{"given":"Pamela","family":"Barraza-Flores","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailey J.","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina R.","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler G.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy T.","family":"Grunert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9228-5258","authenticated-orcid":false,"given":"Dean J.","family":"Burkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,4]]},"reference":[{"key":"235_CR1","doi-asserted-by":"publisher","unstructured":"Mohassel P, Reghan Foley A, B\u00f6nnemann CG. Extracellular matrix-driven congenital muscular dystrophies [Internet]. Matrix Biol. 2018 [cited 2019 Apr 25]. p. 188\u2013204. Available from. https:\/\/doi.org\/10.1016\/j.matbio.2018.06.005.","DOI":"10.1016\/j.matbio.2018.06.005"},{"key":"235_CR2","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.nmd.2017.06.008","volume":"27","author":"M Sframeli","year":"2017","unstructured":"Sframeli M, Sarkozy A, Bertoli M, Astrea G, Hudson J, Scoto M, et al. Congenital muscular dystrophies in the UK population: clinical and molecular spectrum of a large cohort diagnosed over a 12-year period. Neuromuscul Disord. 2017;27:793\u2013803.","journal-title":"Neuromuscul Disord."},{"key":"235_CR3","doi-asserted-by":"crossref","unstructured":"N. D, M. T. Neuromuscular disorders in childhood: a descriptive epidemiological study from western Sweden. Neuromuscul Disord [Internet]. 2000;10:1\u20139. Available from: http:\/\/www.embase.com\/search\/results?subaction = viewrecord&from = export&id = L30006857%0Ahttp:\/\/dx.doi.org\/10.1016\/S0960-8966(99)00055-3.","DOI":"10.1016\/S0960-8966(99)00055-3"},{"key":"235_CR4","doi-asserted-by":"publisher","unstructured":"Nguyen Q, Lim KRQ, Yokota T. Current understanding and treatment of cardiac and skeletal muscle pathology in laminin-\u03b12 chain-deficient congenital muscular dystrophy. Appl Clin Genet [Internet]. 2019 [cited 2019 Aug 22];Volume 12:113\u201330. Available from: https:\/\/doi.org\/10.2147\/TACG.S187481.","DOI":"10.2147\/TACG.S187481"},{"key":"235_CR5","doi-asserted-by":"publisher","first-page":"356","DOI":"10.4103\/0972-2327.186814","volume":"19","author":"K Konkay","year":"2016","unstructured":"Konkay K, Kannan M, Lingappa L, Uppin M, Challa S. Congenital muscular dystrophy with inflammation: diagnostic considerations. Ann Indian Acad Neurol. 2016;19:356.","journal-title":"Ann Indian Acad Neurol."},{"key":"235_CR6","doi-asserted-by":"crossref","unstructured":"Patton BL. Laminins of the neuromuscular system [Internet]. Microsc. Res. Tech. 2000 [cited 2019 Mar 16]. p. 247\u201361. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11054875.","DOI":"10.1002\/1097-0029(20001101)51:3<247::AID-JEMT5>3.0.CO;2-Z"},{"key":"235_CR7","doi-asserted-by":"crossref","unstructured":"Patton BL, Miner JH, Chiu AY, Sanes JR. Distribution and function of laminins in the neuromuscular system of developing, adult, and mutant mice. J Cell Biol [Internet]. 1997 [cited 2019 Mar 16];139:1507\u201321. Available from: http:\/\/www.jcb.org.","DOI":"10.1083\/jcb.139.6.1507"},{"key":"235_CR8","doi-asserted-by":"crossref","unstructured":"Tidball JG, Welc SS, Wehling-Henricks M. Immunobiology of inherited muscular dystrophies. Compr Physiol [Internet]. 2018 [cited 2019 May 8];8:1313\u201356. Available from: https:\/\/onlinelibrary-wiley-com.unr.idm.oclc.org\/doi\/pdf\/10.1002\/cphy.c170052.","DOI":"10.1002\/cphy.c170052"},{"key":"235_CR9","doi-asserted-by":"crossref","unstructured":"Pegoraro E, Cianno B Di, Hoffman EP, Mancias P, Swerdlow SH, Raikow RB, et al. Congenital muscular dystrophy with primary laminin\u00a0\u03b12 (merosin) deficiency presenting as inflammatory myopathy. Ann Neurol [Internet]. 2005 [cited 2019 Jul 9];40:782\u201391. Available from: https:\/\/onlinelibrary-wiley-com.unr.idm.oclc.org\/doi\/pdf\/10.1002\/ana.410400515.","DOI":"10.1002\/ana.410400515"},{"key":"235_CR10","doi-asserted-by":"publisher","unstructured":"Rooney JE, Knapp JR, Hodges BL, Wuebbles RD, Burkin DJ. Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophy. Am J Pathol [Internet]. Elsevier Inc.; 2012;180:1593\u2013602. Available from: https:\/\/doi.org\/10.1016\/j.ajpath.2011.12.019.","DOI":"10.1016\/j.ajpath.2011.12.019"},{"key":"235_CR11","unstructured":"Gawlik KI, Harandi VM, Cheong RY, Peters\u00e9n \u00c5, Durbeej M. Laminin \u03b11 reduces muscular dystrophy in dy2Jmice. Matrix Biol [Internet]. 2018 [cited 2018 Mar 26]; Available from: https:\/\/ac.els-cdn.com\/S0945053X1830043X\/1-s2.0-S0945053X1830043X-main.pdf?_tid = 2812fba9-3b9b-41d3-a452-ac0615da372b&acdnat = 1522110251_a4d296cbed8c6f6ced9d0014538bd588."},{"key":"235_CR12","doi-asserted-by":"crossref","unstructured":"Gawlik KI, Mayer U, Blomberg K, Sonnenberg A, Ekblom P, Durbeej M. Laminin \u03b11 chain mediated reduction of laminin \u03b12 chain deficient muscular dystrophy involves integrin \u03b17\u03b21 and dystroglycan. FEBS Lett [Internet]. 2006 [cited 2019 Aug 15];580:1759\u201365. Available from: https:\/\/febs-onlinelibrary-wiley-com.unr.idm.oclc.org\/doi\/pdf\/10.1016\/j.febslet.2006.02.027.","DOI":"10.1016\/j.febslet.2006.02.027"},{"key":"235_CR13","doi-asserted-by":"crossref","unstructured":"van Ry PM, Minogue P, Hodges BL, Burkin DJ. Laminin-111 improves muscle repair in a mouse model of merosin-deficient congenital muscular dystrophy. Hum Mol Genet [Internet]. Oxford University Press; 2014 [cited 2016 Sep 6];23:383\u201396. Available from: http:\/\/www.hmg.oxfordjournals.org\/cgi\/doi\/10.1093\/hmg\/ddt428.","DOI":"10.1093\/hmg\/ddt428"},{"key":"235_CR14","doi-asserted-by":"crossref","unstructured":"Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, et al. Multiple defects in innate and adaptive immunologic function in NOD\/LtSz-scid mice. J Immunol [Internet]. 1995 [cited 2019 Apr 7];154:180\u201391. Available from: http:\/\/www.jimmunol.org\/content\/154\/1\/180.","DOI":"10.4049\/jimmunol.154.1.180"},{"key":"235_CR15","doi-asserted-by":"crossref","unstructured":"Welser J V, Rooney JE, Cohen NC, Gurpur PB, Singer CA, Evans RA, et al. Myotendinous junction defects and reduced force transmission in mice that lack \u03b17 integrin and utrophin. Am J Pathol [Internet]. 2009 [cited 2019 Jul 11];175:1545\u201354. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2751551\/pdf\/JPATH175001545.pdf.","DOI":"10.2353\/ajpath.2009.090052"},{"key":"235_CR16","doi-asserted-by":"crossref","unstructured":"Barraza-Flores P, Fontelonga TM, Wuebbles RD, Hermann HJ, Nunes AM, Kornegay JN, et al. Laminin-111 protein therapy enhances muscle regeneration and repair in the GRMD dog model of Duchenne muscular dystrophy. Hum Mol Genet [Internet]. 2019 [cited 2019 Jul 11]; Available from: https:\/\/academic.oup.com\/hmg\/advance-article-abstract\/doi\/10.1093\/hmg\/ddz086\/5479258.","DOI":"10.1093\/hmg\/ddz086"},{"key":"235_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.devcel.2018.06.018","volume":"46","author":"MN Wosczyna","year":"2018","unstructured":"Wosczyna MN, Rando TA. A muscle stem cell support group: coordinated cellular responses in muscle regeneration. Dev Cell. 2018;46:135\u201343.","journal-title":"Dev Cell."},{"key":"235_CR18","unstructured":"Kuang W, Xu H, Vilquin JT, Engvall E. Activation of the lama2 gene in muscle regeneration: abortive regeneration in laminin alpha2-deficiency. Lab Invest [Internet]. 1999 [cited 2019 Jul 17];79:1601\u201313. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10616210."},{"key":"235_CR19","doi-asserted-by":"publisher","unstructured":"Yurchenco PD, McKee KK, Reinhard JR, R\u00fcegg MA. Laminin-deficient muscular dystrophy: molecular pathogenesis and structural repair strategies [Internet]. Matrix Biol. 2018 [cited 2019 Feb 4]. p. 174\u201387. Available from: https:\/\/doi.org\/10.1016\/j.matbio.2017.11.009.","DOI":"10.1016\/j.matbio.2017.11.009"},{"key":"235_CR20","doi-asserted-by":"crossref","unstructured":"North KN, Specht LA, Sethi RK, Shapiro F, Beggs AH. Congenital muscular dystrophy associated with merosin deficiency the congenital muscular dystrophies are a heterogeneous group of muscle diseases characterized by early-onset weak-ness, hypotonia, delayed motor milestones, and a high inci-dence of severe [Internet]. J Child Neurol. 1996. Available from: https:\/\/journals-sagepub-com.unr.idm.oclc.org\/doi\/pdf\/10.1177\/088307389601100406.","DOI":"10.1177\/088307389601100406"},{"key":"235_CR21","doi-asserted-by":"crossref","unstructured":"Gawlik KI, Li J-Y, Peters\u00e9n A, Durbeej M. Laminin alpha1 chain improves laminin alpha2 chain deficient peripheral neuropathy. Hum Mol Genet [Internet]. 2006;15:2690\u2013700. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16893907.","DOI":"10.1093\/hmg\/ddl201"},{"key":"235_CR22","doi-asserted-by":"crossref","unstructured":"Rooney JE, Gurpur PB, Burkin DJ. Laminin-111 protein therapy prevents muscle disease in the mdx mouse model for Duchenne muscular dystrophy. Proc Natl Acad Sci U S A. United States; 2009. p. 7991\u20136.","DOI":"10.1073\/pnas.0811599106"},{"key":"235_CR23","doi-asserted-by":"publisher","unstructured":"Riederer I, Bonomo AC, Mouly V, Savino W. Laminin therapy for the promotion of muscle regeneration. FEBS Lett [Internet]. Federation of European Biochemical Societies; 2015 [cited 2019 Jun 14];589:3449\u201353. Available from: https:\/\/doi.org\/10.1016\/j.febslet.2015.10.004.","DOI":"10.1016\/j.febslet.2015.10.004"},{"key":"235_CR24","doi-asserted-by":"crossref","unstructured":"Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research [Internet]. Nat. Rev. Immunol. 2007 [cited 2019 Apr 10]. p. 118\u201330. Available from: www.nature.com\/reviews\/immunol.","DOI":"10.1038\/nri2017"},{"key":"235_CR25","unstructured":"Mice CB, Greiner DL, Shultz LD, Yates J, Appel MC, Perdrizet G, et al. Improved engraftment of human spleen cells in NODILtSz-scid\/scid mice as compared with C.B-1 7-scid\/scid Mice. Am J Pathol [Internet]. 1995 [cited 2019 Jul 9];146:888\u2013902. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC1869266\/pdf\/amjpathol00052-0110.pdf."},{"key":"235_CR26","doi-asserted-by":"crossref","unstructured":"Prochazka M, Gaskins HR, Shultz LD, Leiter EH. The nonobese diabetic scid mouse: Model for spontaneous thymomagenesis associated with immunodeficiency (severe combined immunodeficiency mutation). Immunology [Internet]. 1992;89:3290\u20134. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC48852\/pdf\/pnas01082-0136.pdf.","DOI":"10.1073\/pnas.89.8.3290"},{"key":"235_CR27","doi-asserted-by":"crossref","unstructured":"Pegoraro E, Mancias P, Swerdlow SH, Raikow RB, Garcia C, Marks H, et al. Congenital muscular dystrophy with primary laminin-a2 (Merosin) deficiency presenting as inflammatory myopathy. Am Neurol Assoc [Internet]. 1996 [cited 2019 May 13];782\u201391. Available from: https:\/\/onlinelibrary-wiley-com.unr.idm.oclc.org\/doi\/pdf\/10.1002\/ana.410400515.","DOI":"10.1002\/ana.410400515"},{"key":"235_CR28","doi-asserted-by":"crossref","unstructured":"Fontes-Oliveira CC, M. Soares Oliveira B, K\u00f6rner Z, M. Harandi V, Durbeej M. Effects of metformin on congenital muscular dystrophy type 1A disease progression in mice: a gender impact study. Sci Rep [Internet]. 2018 [cited 2019 Apr 24];8. Available from: www.nature.com\/scientificreports\/.","DOI":"10.1038\/s41598-018-34362-2"}],"container-title":["Skeletal Muscle"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13395-020-00235-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13395-020-00235-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13395-020-00235-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T18:41:26Z","timestamp":1696185686000},"score":1,"resource":{"primary":{"URL":"https:\/\/skeletalmusclejournal.biomedcentral.com\/articles\/10.1186\/s13395-020-00235-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,4]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["235"],"URL":"https:\/\/doi.org\/10.1186\/s13395-020-00235-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-29430\/v1","asserted-by":"object"}]},"ISSN":["2044-5040"],"issn-type":[{"value":"2044-5040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,4]]},"assertion":[{"value":"14 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All vertebrate animal studies described in this manuscript were performed under an animal protocol (#00404) approved by the University of Nevada, Reno IACUC.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The University of Nevada, Reno, has a patent on the therapeutic use of laminin-111 and its derivatives. This patent has been licensed to Prothelia Inc., and the University of Nevada, Reno, has a small equity share in this company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}